ClinicalTrials.gg

Program

JBI-778

Its studies are mostly in Carcinoma, Adenoid Cystic · Meningeal Neoplasms, led by 2 companies.

Furthest: phase 2, since Aug 3, 20262 company-led studies, 2 open or runningNext primary completion: Mar 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jubilant Therapeutics11 open or runningphase 2since Aug 3, 2026Aug 3, 2026Mar 31, 2030phase 2 · NCT07751744
Jubilant Therapeutics India11 open or runningphase 1since Aug 5, 2026Aug 5, 2026Mar 2028phase 1 · NCT07755397

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 3, 2026First study: phase 2 study in Meningeal NeoplasmsNew to Jubilant TherapeuticsJubilant Therapeutics · NCT07751744 · 113 planned
  2. Aug 5, 2026Jubilant Therapeutics India’s first study: phase 1 study in NSCLC Patients With EGFR Activating MutationNew to Jubilant Therapeutics IndiaJubilant Therapeutics India · NCT07755397 · 30 planned · India

Ahead

  1. Mar 2028Primary completion: phase 1 study in NSCLC Patients With EGFR Activating MutationJubilant Therapeutics India · NCT07755397
  2. Mar 31, 2030Primary completion: phase 2 study in Meningeal NeoplasmsJubilant Therapeutics · NCT07751744

TargetBeta

PRMT5 →read by rule
“JBI-778 is an orally administered selective PRMT5 inhibitor supplied as capsules.”study text, by rule · the study

Other programs on PRMT5

ProgramCompanyFurthest phaseStudies
navlimetostatBristol-Myers Squibbphase 310
PRMT5 Inhibitor AZD3470AstraZenecaphase 22
PRMT5 Inhibitor TNG456ruletango-therapeutics-incphase 21
PRMT5 Inhibitor BAY 3713372ruleBayerphase 21
onametostatruleJohnson & Johnsonphase 12
PRMT5 Inhibitor SH3765ruleNanjing Sanhome Pharmaceuticalphase 12
PRMT5 Inhibitor BGB-58067ruleBeOne Medicinesphase 12
PRMT5 Inhibitor IDE892ruleideaya-biosciencesphase 11
PEP08rulepharmaenginephase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07755397NSCLC Patients With EGFR Activating Mutation · India1RecruitingJubilant Therapeutics IndiaMar 202830
NCT07751744Meningeal Neoplasms2Not yet recruitingJubilant TherapeuticsMar 31, 2030113

How it is read

Names in the registry

  • “JBI-778”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.